Search Results for 'lead investigator for the remyelination study'
1 results found.
Good news for Elan as study illustrates Tysabri MS success
![image preview](/images/2009/04/11567_thumb.jpg)
Athlone-based drug developer and its US partner, Biogen Idec, last evening hailed success from a study into the effects of their MS drug, Tysabri in repairing damage to the myelin sheath, a key cause of MS.